Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparison of subconjunctival microinvasive glaucoma surgery and trabeculectomy

Comparison of subconjunctival microinvasive glaucoma surgery and trabeculectomy IntroductionGlobally, glaucoma is a disease affecting about 60.5 million people worldwide (Quigley & Broman 2006). It accounts for 8% of all cases of blindness and is the second leading cause of irreversible blindness worldwide. (Pascolini & Mariotti 2012). Initial therapy for glaucoma typically consists of topical eye drops or laser trabeculoplasty, both of which aim to lower intraocular pressure and have similar efficacy. (Samples et al. 2011) When pharmacologic and/or laser treatment fails to control intraocular pressure (IOP), pressure‐lowering surgery is required. Due to its effective reduction of the intraocular pressure and its cost efficiency, trabeculectomy is considered the reference standard in surgical treatment of glaucoma (Kirwan et al. 2013).However, recent developments have led to an expansion of the therapeutic options. For instance, a new group of procedures is pursuing a less invasive approach, aiming to reduce possible complications. Minimal Invasive Glaucoma Surgery (MIGS) includes a variety of interventions, extending from miniaturized versions of trabeculectomy to minimally invasive shunt or bypass operations, differing from traditional tube shunt procedures through limited surgical manipulation of the sclera and the conjunctiva (Burr et al. 2005).Amongst these alternative procedures, the XEN45® gelstent (Allergan, Dublin, Ireland) was introduced in 2016 – a 6 mm porcine gelatin implant with a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Ophthalmologica Wiley

Comparison of subconjunctival microinvasive glaucoma surgery and trabeculectomy

Loading next page...
 
/lp/wiley/comparison-of-subconjunctival-microinvasive-glaucoma-surgery-and-q6AhSyOK8i

References (36)

Publisher
Wiley
Copyright
Copyright © 2022 Acta Ophthalmologica Scandinavica Foundation
ISSN
1755-375X
eISSN
1755-3768
DOI
10.1111/aos.15042
Publisher site
See Article on Publisher Site

Abstract

IntroductionGlobally, glaucoma is a disease affecting about 60.5 million people worldwide (Quigley & Broman 2006). It accounts for 8% of all cases of blindness and is the second leading cause of irreversible blindness worldwide. (Pascolini & Mariotti 2012). Initial therapy for glaucoma typically consists of topical eye drops or laser trabeculoplasty, both of which aim to lower intraocular pressure and have similar efficacy. (Samples et al. 2011) When pharmacologic and/or laser treatment fails to control intraocular pressure (IOP), pressure‐lowering surgery is required. Due to its effective reduction of the intraocular pressure and its cost efficiency, trabeculectomy is considered the reference standard in surgical treatment of glaucoma (Kirwan et al. 2013).However, recent developments have led to an expansion of the therapeutic options. For instance, a new group of procedures is pursuing a less invasive approach, aiming to reduce possible complications. Minimal Invasive Glaucoma Surgery (MIGS) includes a variety of interventions, extending from miniaturized versions of trabeculectomy to minimally invasive shunt or bypass operations, differing from traditional tube shunt procedures through limited surgical manipulation of the sclera and the conjunctiva (Burr et al. 2005).Amongst these alternative procedures, the XEN45® gelstent (Allergan, Dublin, Ireland) was introduced in 2016 – a 6 mm porcine gelatin implant with a

Journal

Acta OphthalmologicaWiley

Published: Aug 1, 2022

Keywords: glaucoma; MIGS; trabeculectomy; surgical glaucoma treatment; filtration surgery

There are no references for this article.